⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
prnewswire.com
SNGX
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
prnewswire.com
SNGX
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
prnewswire.com
SNGX
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
globenewswire.com
SNGX
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
prnewswire.com
SNGX
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
prnewswire.com
SNGX
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
prnewswire.com
SNGX
ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update
businesswire.com
SNGX
NVO
Soligenix to Present at BIO Investment & Growth Summit
prnewswire.com
SNGX
Soligenix Details Recent Progress and Upcoming Milestones
prnewswire.com
SNGX